Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Tamoxifen use in postmenopausal breast cancer: CYP2D6 matters.

Literature DB >> 23091108

Tamoxifen use in postmenopausal breast cancer: CYP2D6 matters.

Hiltrud Brauch¹, Werner Schroth, Matthew P Goetz, Thomas E Mürdter, Stefan Winter, James N Ingle, Matthias Schwab, Michel Eichelbaum.

Abstract

Entities: Chemical Disease Gene

Mesh：

Substances：

Year: 2012 PMID： 23091108 PMCID： PMC3731938 DOI： 10.1200/JCO.2012.44.6625

Source DB: PubMed Journal: J Clin Oncol ISSN： 0732-183X Impact factor: 44.544

× No keyword cloud information.

32 in total

Review 1. Hormonal effects of aromatase inhibitors: focus on premenopausal effects and interaction with tamoxifen.

Authors: M Dowsett; B P Haynes
Journal: J Steroid Biochem Mol Biol Date: 2003-09 Impact factor: 4.292

2. Re: Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine.

Authors: Brooke Ratliff; Eric C Dietze; Gregory R Bean; Cassandra Moore; Sam Wanko; Victoria L Seewaldt
Journal: J Natl Cancer Inst Date: 2004-06-02 Impact factor: 13.506

3. Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial.

Authors: Vincent Stanton
Journal: J Natl Cancer Inst Date: 2012-07-31 Impact factor: 13.506

4. A region of deletion on chromosome 22q13 is common to human breast and colorectal cancers.

Authors: A Castells; J F Gusella; V Ramesh; A K Rustgi
Journal: Cancer Res Date: 2000-06-01 Impact factor: 12.701

5. Allelic losses as prognostic markers for breast cancers.

Authors: A Hirano; Y Utada; S Haga; T Kajiwara; G Sakamoto; F Kasumi; Y Nakamura; M Emi
Journal: Int J Clin Oncol Date: 2001-02 Impact factor: 3.402

6. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine.

Authors: Vered Stearns; Michael D Johnson; James M Rae; Alan Morocho; Antonella Novielli; Pankaj Bhargava; Daniel F Hayes; Zeruesenay Desta; David A Flockhart
Journal: J Natl Cancer Inst Date: 2003-12-03 Impact factor: 13.506

7. Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen.

Authors: Michael D Johnson; Hong Zuo; Kyung-Hoon Lee; Joseph P Trebley; James Michael Rae; Ross V Weatherman; Zeruesanay Desta; David A Flockhart; Todd C Skaar
Journal: Breast Cancer Res Treat Date: 2004-05 Impact factor: 4.872

8. A randomized trial of low-dose tamoxifen on breast cancer proliferation and blood estrogenic biomarkers.

Authors: Andrea Decensi; Chris Robertson; Giuseppe Viale; Francesca Pigatto; Harriet Johansson; Elton R Kisanga; Paolo Veronesi; Rosalba Torrisi; Massimiliano Cazzaniga; Serena Mora; Maria T Sandri; Giuseppe Pelosi; Alberto Luini; Aron Goldhirsch; Ernst A Lien; Umberto Veronesi
Journal: J Natl Cancer Inst Date: 2003-06-04 Impact factor: 13.506

Review 9. Genotype-guided tamoxifen therapy: time to pause for reflection?

Authors: Timothy L Lash; Ernst A Lien; Henrik Toft Sørensen; Stephen Hamilton-Dutoit
Journal: Lancet Oncol Date: 2009-08 Impact factor: 41.316

10. Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial and Re: CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients.

Authors: Paul D P Pharoah; Jean Abraham; Carlos Caldas
Journal: J Natl Cancer Inst Date: 2012-07-31 Impact factor: 13.506

41 in total

1. Do we need another selective estrogen receptor modulator for the adjuvant treatment of breast cancer?

Authors: T Shenkier
Journal: Curr Oncol Date: 2013-08 Impact factor: 3.677

Review 2. Challenges in pharmacogenetics.

Authors: Ingolf Cascorbi; Oliver Bruhn; Anneke N Werk
Journal: Eur J Clin Pharmacol Date: 2013-05-03 Impact factor: 2.953

3. Breast cancer recurrence in relation to antidepressant use.

Authors: Jessica Chubak; Erin J A Bowles; Onchee Yu; Diana S M Buist; Monica Fujii; Denise M Boudreau
Journal: Cancer Causes Control Date: 2015-10-30 Impact factor: 2.506

4. CYP2D6 genotyping and tamoxifen in the treatment of post-menopausal breast cancer - a reply.

Authors: Hiltrud Brauch; Matthias Schwab
Journal: Br J Clin Pharmacol Date: 2014-08 Impact factor: 4.335

5. Re: Concordance between CYP2D6 genotypes obtained from tumor-derived and germline DNA.

Authors: Matthew P Goetz; Hiltrud Brauch; Mark J Ratain; Nancy J Cox; Yusuke Nakamura; Richard Weinshilboum; James N Ingle
Journal: J Natl Cancer Inst Date: 2014-04-03 Impact factor: 13.506

Review 6. Pharmacogenomics in the clinic.

Authors: Mary V Relling; William E Evans
Journal: Nature Date: 2015-10-15 Impact factor: 49.962

7. Loss of heterozygosity at the CYP2D6 locus in breast cancer: implications for germline pharmacogenetic studies.

Authors: Matthew P Goetz; James X Sun; Vera J Suman; Grace O Silva; Charles M Perou; Yusuke Nakamura; Nancy J Cox; Philip J Stephens; Vincent A Miller; Jeffrey S Ross; David Chen; Stephanie L Safgren; Mary J Kuffel; Matthew M Ames; Krishna R Kalari; Henry L Gomez; Ana M Gonzalez-Angulo; Octavio Burgues; Hiltrud B Brauch; James N Ingle; Mark J Ratain; Roman Yelensky
Journal: J Natl Cancer Inst Date: 2014-12-08 Impact factor: 13.506